Literature DB >> 18082588

Intensity-modulated radiation therapy: supportive data for prostate cancer.

Oren Cahlon1, Margie Hunt, Michael J Zelefsky.   

Abstract

Since its introduction into clinical use in the mid-1990s, intensity-modulated radiation therapy (IMRT) has emerged as the most effective and widely used form of external-beam radiotherapy for localized prostate cancer. Multiple studies have confirmed the importance of delivering sufficiently high doses to the prostate to achieve cure. The dosimetric superiority of IMRT over conventional techniques to produce conformal dose distributions that allow for organ sparing has been shown. A growing number of reports have confirmed that IMRT is the safest way to deliver high doses of external-beam irradiation to the prostate and the regional lymph nodes. Advances in imaging and onboard verification systems continue to advance the capabilities of IMRT and have potential implications with regards to further dose escalation and hypofractionated regimens. The clinical data in support of IMRT and the associated technical aspects of IMRT treatment planning and implementation are highlighted in this review.

Entities:  

Mesh:

Year:  2008        PMID: 18082588     DOI: 10.1016/j.semradonc.2007.09.007

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  38 in total

Review 1.  Robotic prostate biopsy and its relevance to focal therapy of prostate cancer.

Authors:  Henry Ho; John S P Yuen; Christopher W S Cheng
Journal:  Nat Rev Urol       Date:  2011-09-20       Impact factor: 14.432

Review 2.  Technological advances in radiotherapy for esophageal cancer.

Authors:  Milan Vosmik; Jiri Petera; Igor Sirak; Miroslav Hodek; Petr Paluska; Jiri Dolezal; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

3.  A new view of radiation-induced cancer.

Authors:  I Shuryak; R K Sachs; D J Brenner
Journal:  Radiat Prot Dosimetry       Date:  2010-11-27       Impact factor: 0.972

4.  Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

Authors:  Berna A Yildirim; Cem Onal; Yemliha Dolek
Journal:  Jpn J Radiol       Date:  2016-10-11       Impact factor: 2.374

5.  The relationship between clinical benefit and receipt of curative therapy for prostate cancer.

Authors:  Ann C Raldow; Carolyn J Presley; James B Yu; Richa Sharma; Laura D Cramer; Pamela R Soulos; Jessica B Long; Danil V Makarov; Cary P Gross
Journal:  Arch Intern Med       Date:  2012-02-27

6.  Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.

Authors:  Martin Dolezel; Karel Odrazka; Milan Zouhar; Miloslava Vaculikova; Jana Sefrova; Jan Jansa; Petr Paluska; Tereza Kohlova; Jaroslav Vanasek; Josef Kovarik
Journal:  Strahlenther Onkol       Date:  2015-01-15       Impact factor: 3.621

7.  Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

Authors:  James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2012-12-14       Impact factor: 13.506

8.  Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer.

Authors:  Hideki Takeshita; Noboru Numao; Toshiki Kijima; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Fumitaka Koga; Kazutaka Saito; Hitoshi Masuda; Satoru Kawakami; Shinya Yamamoto; Junji Yonese; Yasuhisa Fujii; Kazunori Kihara
Journal:  Int Urol Nephrol       Date:  2013-03-26       Impact factor: 2.370

Review 9.  A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer.

Authors:  Patricia Diez; Ivan S Vogelius; Søren M Bentzen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-31       Impact factor: 7.038

10.  Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity.

Authors:  Sonia Drozdz; Michael Schwedas; Henning Salz; Susan Foller; Thomas G Wendt
Journal:  Strahlenther Onkol       Date:  2016-01-07       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.